Groupe d'Oncologie Radiothérapie Tête et Cou

Recent papers from Groupe d'Oncologie Radiothérapie Tête et Cou

1. Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trialThe Lancet · 2025
2. Comment prévenir et gérer les toxicités hématologiques liées aux inhibiteurs de PARP dans le cancer de la prostate ?Bulletin du Cancer · 2026
3. Psychological flexibility buffers the impact of negative anticipation and fear of childbirth on prenatal depressive symptoms: insights from the first phase of the flexi-prep cohort studyMidwifery · 2026
4. Defining physician acceptance of radiosensitivity testing for guiding therapeutic interventions in head and neck cancer: A Delphi consensus studyClinical and Translational Radiation Oncology · 2026
5. Robust automatic soft tissue flap segmentation using a challenging case-enriched nnU-Net in head and neck CT imagesScientific Reports · 2026
6. Contemporary Surgical Outcomes and Repair Rates in Degenerative Mitral Regurgitation: Real World Insights from the International MITRACURE RegistryJournal of Thoracic and Cardiovascular Surgery · 2026
7. The assessment of fire damaged street furniture in Lahaina, Maui, using YOLOv12 and 360° imageryTransportation Research Interdisciplinary Perspectives · 2026
8. Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNEESMO Open · 2026
9. Analyse des pratiques de traitement des carcinomes épidermoïdes localement avancés de la tête et du cou : une enquête du GORTECBulletin du Cancer · 2026
10. Missed Opportunity for Fibrinolysis in ST-Segment–Elevation Myocardial Infarction: The Nationwide France-PCI RegistryEuropean Heart Journal - Quality of Care and Clinical Outcomes · 2026
11. Hypofractionated split-course versus standard radiotherapy in frail older patients with head and neck squamous-cell carcinoma (ELAN-RT trial): a non-inferiority, multicentre, open-label, randomised controlled trialThe Lancet Healthy Longevity · 2026
12. Clinical outcome of advanced or recurrent endometrial carcinoma treated with chemotherapy: a French observational retrospective cohort: the ENDOVIE studyBMJ Open · 2025
13. Auto-Segmentation via deep-learning approaches for the assessment of flap volume after reconstructive surgery or radiotherapy in head and neck cancerScientific Reports · 2025
14. Development and validation of the participatory approach questionnaire (PARTAQUE) in cancer teams: a ready-to-use tool for enhancing the quality of work life for caregiversFrontiers in Psychology · 2025
15. Exposure–response relationship of niraparib in maintenance therapy for recurrent ovarian cancer: ancillary analysis of the French GINECO–NiQoLe studyESMO Open · 2025
16. Pantethine Therapy Dramatically Rescues End-Stage Failing Heart in a Patient with Deficiency of Coenzyme A BiosynthesisESC Heart Failure · 2025
17. Clinical usefulness of anti-α3Gal immunoglobulin E assays for cetuximab-mediated anaphylaxis in head and neck cancerImmuno-Oncology Technology · 2025
18. Cost-minimization analysis of the GORTEC 2014-04 randomized phase II study of stereotactic ablative radiotherapy (SABR) or chemotherapy-SABR in oligometastatic head and neck cancerRadiotherapy and Oncology · 2025
19. Survival Without Quality of Life Deterioration in the GORTEC 2014-04 “OMET” Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABRInternational Journal of Radiation Oncology*Biology*Physics · 2024
20. Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line TreatmentEuropean Urology Oncology · 2024